Monlunabant

Skye Bioscience's novel CB1 antibody nimacimab demonstrated 23.5% weight loss as monotherapy in diet-induced obesity models, comparable to effects seen with tirzepatide and monlunabant.

Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial of CRB-913, a second-generation CB1 inverse agonist designed to treat obesity while avoiding neuropsychiatric side effects.

Novo Nordisk's amycretin, a GLP-1 and amylin receptor agonist, demonstrated significant weight loss in a Phase 1b/2a trial.

Corbus Pharmaceuticals presented Phase 1 data for CRB-701, a Nectin-4 targeting antibody-drug conjugate, at the ASCO Genitourinary Cancers Symposium.

The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.